{"id":"afolia","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets folate receptor alpha, which is expressed on immune cells and reproductive tissues. By modulating FRα signaling, AFOLIA aims to improve reproductive function and fertility outcomes. The exact immunological or reproductive mechanism in Phase 3 development remains proprietary to Fertility Biotech AG.","oneSentence":"AFOLIA is a folate receptor alpha (FRα) antagonist designed to modulate immune responses and enhance fertility outcomes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:07.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infertility or subfertility (indication under Phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT02459418","phase":"PHASE1","title":"Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application","status":"COMPLETED","sponsor":"Fertility Biotech AG","startDate":"2015-05-07","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT01687712","phase":"PHASE3","title":"Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF","status":"COMPLETED","sponsor":"Fertility Biotech AG","startDate":"2013-11-25","conditions":"Infertility","enrollment":1100},{"nctId":"NCT01121666","phase":"PHASE3","title":"Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment","status":"COMPLETED","sponsor":"Finox AG","startDate":"2010-06","conditions":"Infertility","enrollment":460},{"nctId":"NCT01141270","phase":"PHASE1","title":"Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application","status":"COMPLETED","sponsor":"Polymun Scientific GmbH","startDate":"2009-01","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Follitropin-alfa","Follitropin Alfa"],"phase":"phase_3","status":"active","brandName":"AFOLIA","genericName":"AFOLIA","companyName":"Fertility Biotech AG","companyId":"fertility-biotech-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AFOLIA is a folate receptor alpha (FRα) antagonist designed to modulate immune responses and enhance fertility outcomes. Used for Infertility or subfertility (indication under Phase 3 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}